Core Viewpoint - Bitcoin Depot Inc. (BTM) is experiencing solid improvement in earnings estimates, which may lead to continued short-term price momentum for the stock [1][2]. Earnings Estimate Revisions - The rising trend in earnings estimate revisions reflects growing analyst optimism about Bitcoin Depot Inc.'s earnings prospects, which is expected to positively impact its stock price [2]. - The current-quarter earnings estimate is projected at $0.17 per share, indicating a year-over-year increase of +230.77%. The Zacks Consensus Estimate has risen by 36% over the last 30 days, with three estimates increasing and one decreasing [5]. - For the full year, the earnings estimate is expected to be $0.46 per share, representing a change of +176.67% from the previous year. The consensus estimate has increased by 34.56% due to three upward revisions and one downward revision [6][7]. Zacks Rank and Performance - Bitcoin Depot Inc. currently holds a Zacks Rank 2 (Buy), indicating promising estimate revisions. Stocks with Zacks Rank 1 (Strong Buy) and 2 (Buy) have historically outperformed the S&P 500 [8]. - The stock has appreciated by 114.2% over the past four weeks due to strong estimate revisions, suggesting potential for further upside [9].

Core Viewpoint - Bitcoin Depot Inc. has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Bitcoin Depot Inc. is expected to earn $0.46 per share for the fiscal year ending December 2025, reflecting a year-over-year change of 176.7% [8]. - Over the past three months, the Zacks Consensus Estimate for Bitcoin Depot Inc. has increased by 98.9% [8]. Investment Implications - The upgrade to Zacks Rank 2 positions Bitcoin Depot Inc. in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10]. - Rising earnings estimates and the corresponding rating upgrade indicate an improvement in the company's underlying business, which could lead to increased stock prices [5][10].

Group 1 - Coinbase's first-quarter results did not meet investor expectations [1] - The company is set to acquire Deribit for $2.9 billion, which may significantly impact its growth [1] - The acquisition is expected to enhance Coinbase's position in the crypto services market [1]

Core Viewpoint - A class action lawsuit has been filed against Bakkt Holdings, Inc. for allegedly misleading investors about the stability and diversity of its crypto services revenue, particularly its reliance on a single contract with Webull [1][2]. Group 1: Allegations and Financial Impact - The complaint alleges that Bakkt misrepresented the stability and diversity of its crypto services revenue and failed to disclose its substantial dependence on a single contract with Webull [2]. - Bakkt disclosed that Webull accounted for 74% of its crypto services revenue for the nine months ending September 30, 2024, and that 98% of its total revenue came from crypto services during the same period [3]. - Following the announcement of Webull's termination of their commercial agreement, Bakkt is expected to face a 73% loss in top-line revenue, leading to a significant drop in share price by $3.50 or 27.3% to close at $9.33 per share on March 18, 2025 [3]. Group 2: Legal Proceedings and Participation - Shareholders are encouraged to participate in the class action against Bakkt Holdings, with options to serve as lead plaintiff or remain an absent class member [4]. - Robbins LLP operates on a contingency fee basis, meaning shareholders will incur no fees or expenses for representation [5].

Core Viewpoint - Class actions have been initiated on behalf of stockholders of Solaris Energy Infrastructure, Actinium Pharmaceuticals, Bakkt Holdings, and Cerevel Therapeutics, with specific allegations of misleading statements and omissions of material facts regarding their business operations and prospects [1]. Solaris Energy Infrastructure, Inc. (NYSE: SEI) - Class period is from July 9, 2024, to March 17, 2025, with a lead plaintiff deadline of May 27, 2025 [2]. - Allegations include failure to disclose that Mobile Energy Rentals LLC had minimal corporate history, lacked a diversified earnings stream, and was co-owned by a convicted felon associated with turbine-related fraud [2]. - Claims that Solaris overstated commercial prospects from an acquisition and inflated profitability metrics by not properly depreciating turbines, leading to materially misleading statements [2]. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) - Class period is from October 31, 2022, to August 2, 2024, with a lead plaintiff deadline of May 26, 2025 [3]. - The complaint alleges that Actinium made false claims regarding the strength of data submitted to the FDA for its Biologics License Application for Iomab-B, later admitting the need for additional clinical trials [3]. - Public statements were deemed materially misleading, resulting in investor damages when the truth was revealed [3]. Bakkt Holdings, Inc. (NYSE: BKKT) - Class period is from March 25, 2024, to March 17, 2025, with a lead plaintiff deadline of June 2, 2025 [4]. - Allegations include misrepresentation of the stability and diversity of crypto services revenue, which was heavily reliant on a single contract with Webull [4]. - Positive statements about the company's business were claimed to be materially misleading due to undisclosed dependencies [4]. Cerevel Therapeutics Holdings, Inc. (CERE) - Class period is from October 11, 2023, to August 1, 2024, with a lead plaintiff deadline of June 3, 2025 [6]. - The complaint alleges that Cerevel's offering documents omitted material facts about AbbVie's interest in acquiring the company at a significantly higher price than the offering price of $22.81 per share [6]. - Claims that Cerevel's controlling shareholder acquired shares at an artificially depressed price while possessing nonpublic information, leading to a substantial windfall when AbbVie announced the acquisition at $45 per share [6][7].

Core Viewpoint - Investors in Bakkt Holdings, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misrepresentations regarding the company's revenue stability and client relationships [1][2]. Group 1: Lawsuit Details - The lawsuit claims that from March 25, 2024, to March 17, 2025, Bakkt misrepresented the stability and diversity of its crypto services revenue [2]. - It is alleged that Bakkt failed to disclose that its crypto services revenue was heavily reliant on a single contract with Webull [2]. - The complaint states that Bakkt misrepresented its ability to maintain key client relationships, leading to materially misleading statements about the company's business and prospects [2]. Group 2: Participation Information - Investors who suffered losses in Bakkt are encouraged to participate in the ongoing securities fraud lawsuit, with a lead plaintiff deadline set for June 2, 2025 [2]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].